Acute myeloid leukemia targets for bispecific antibodies.
作者信息
Hoseini S S, Cheung N K
出版信息
Blood Cancer J. 2017 Apr 14;7(4):e552. doi: 10.1038/bcj.2017.35.
Abstract
摘要
相似文献
1
Acute myeloid leukemia targets for bispecific antibodies.双特异性抗体的急性髓系白血病靶点
Blood Cancer J. 2017 Apr 14;7(4):e552. doi: 10.1038/bcj.2017.35.
2
Acute myeloid leukemia targets for bispecific antibodies.双特异性抗体的急性髓系白血病靶点
Blood Cancer J. 2017 Feb 3;7(2):e522. doi: 10.1038/bcj.2017.2.
3
Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.噬咬抑制：双特异性 T 细胞衔接抗体为急性髓系白血病治疗带来新希望
Expert Rev Hematol. 2014 Jun;7(3):317-9. doi: 10.1586/17474086.2014.896190. Epub 2014 Mar 11.
4
5
Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.通过一种新型连接子模块可以避免单链双特异性抗 CD3-抗 CD33 抗体的意外重组。
Mol Immunol. 2011 Dec;49(3):474-82. doi: 10.1016/j.molimm.2011.09.019. Epub 2011 Oct 19.
6
The role of CD33 as therapeutic target in acute myeloid leukemia.CD33 在急性髓系白血病中的治疗靶点作用。
Expert Opin Ther Targets. 2014 Jul;18(7):715-8. doi: 10.1517/14728222.2014.909413. Epub 2014 Apr 21.
7
Reasons for optimism in the therapy of acute leukemia.急性白血病治疗中值得乐观的理由。
Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):69-72. doi: 10.1016/j.beha.2015.10.002. Epub 2015 Oct 22.
8
Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).双特异性抗体介导的携带CD15肿瘤免疫疗法的初步试验：使用由抗CD15（单克隆抗体PM81）和抗CD64/FcγRI（单克隆抗体32）组成的双特异性抗体对人肿瘤细胞的细胞毒性
J Hematother. 1992 Spring;1(1):85-94. doi: 10.1089/scd.1.1992.1.85.
9
Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?急性髓系白血病的抗原特异性免疫疗法：我们目前的状况如何，以及未来何去何从？
Expert Rev Hematol. 2016;9(4):335-50. doi: 10.1586/17474086.2016.1142868. Epub 2016 Feb 6.
10
Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.单克隆抗体和免疫偶联物在急性髓系白血病治疗中的整合应用。
Curr Opin Hematol. 2008 Mar;15(2):95-100. doi: 10.1097/MOH.0b013e3282f3de84.
引用本文的文献
1
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions.抗髓系白血病细胞的单克隆抗体：当前认知与未来方向。
Int J Mol Sci. 2025 May 10;26(10):4571. doi: 10.3390/ijms26104571.
2
Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia.针对小儿急性髓系白血病的 CD33 靶向双药物载纳米粒子的研发。
Biomacromolecules. 2024 Oct 14;25(10):6503-6514. doi: 10.1021/acs.biomac.4c00672. Epub 2024 Sep 5.
3
Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?急性髓系白血病的疫苗接种疗法：我们目前的状况如何？
Cancers (Basel). 2022 Jun 17;14(12):2994. doi: 10.3390/cancers14122994.
4
Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.双特异性抗体为基础的免疫细胞衔接器及其在癌症免疫治疗中的新兴治疗靶点。
Int J Mol Sci. 2022 May 19;23(10):5686. doi: 10.3390/ijms23105686.
5
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.一种新型 IgG 型 FLT3xCD3 双特异性抗体，用于治疗 AML 和 B-ALL。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003882.
6
BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?双特异性T细胞衔接器（BiTEs）、双特异性抗体招募T细胞（DARTS）、双特异性激酶招募器（BiKEs）和三特异性激酶招募器（TriKEs）——基于抗体的疗法正在改变急性髓系白血病（AML）的未来治疗吗？
Life (Basel). 2021 May 23;11(6):465. doi: 10.3390/life11060465.
7
Aberrant Phenotypes in Acute Myeloid Leukemia and Its Relationship with Prognosis and Survival: A Systematic Review and Meta-Analysis.急性髓系白血病的异常表型及其与预后和生存的关系：一项系统评价和荟萃分析
Int J Hematol Oncol Stem Cell Res. 2020 Oct 1;14(4):274-288. doi: 10.18502/ijhoscr.v14i4.4484.
8
Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.针对急性髓系白血病中白血病干细胞的基于细胞和抗体的免疫疗法：观点和未解决的问题。
Stem Cells Transl Med. 2020 Nov;9(11):1331-1343. doi: 10.1002/sctm.20-0147. Epub 2020 Jul 13.
9
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.用于急性髓系白血病的嵌合抗原受体T细胞：现状与未来方向
Front Oncol. 2020 May 6;10:697. doi: 10.3389/fonc.2020.00697. eCollection 2020.
10
Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study.椭圆酮类化合物抗白血病活性的建模：定量构效关系和分子对接研究。
Molecules. 2019 Dec 19;25(1):24. doi: 10.3390/molecules25010024.
Zotero 插件